-+ 0.00%
-+ 0.00%
-+ 0.00%

Celldex Reports Topline Results From Phase 2 Study Of Barzolvolimab In Atopic Dermatitis; Study Did Not Meet Key Efficacy Measures Or Internal Hurdle Rate For Continued Development

Benzinga·11/19/2026 21:03:32
Listen to the news
  • Study did not meet key efficacy measures or internal hurdle rate for continued development
  • Systemic mast cell depletion observed, consistent with prior studies, as evidenced by significant reduction in serum tryptase
  • Favorable safety and tolerability demonstrated, consistent with prior studies
  • BLA submission for barzolvolimab in CSU anticipated in 2027
  • Phase 3 barzolvolimab cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) actively enrolling
  • Additional indications for barzolvolimab to be announced by year end

HAMPTON, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported topline results from the Company’s Phase 2 study of barzolvolimab in moderate to severe atopic dermatitis (AD). Barzolvolimab, a first-in-class humanized monoclonal antibody with a novel mechanism of action that uniquely targets the KIT receptor and depletes mast cells, is being studied across multiple indications where mast cells are implicated in the disease pathology. The primary endpoint of the Phase 2 AD study, the percent change from baseline in the weekly average of the daily Peak Pruritus Numerical Rating Scale (PP-NRS) score at Week 16 compared to placebo, and key secondary endpoints were not met. While some benefit from barzolvolimab treatment was observed, these improvements did not meet the Company’s internal hurdle rate for continued development. Data suggest that while mast cells contribute to AD, they are not a primary driver of the disease. Based on these results, Celldex is discontinuing development in AD. Consistent with previously reported studies, barzolvolimab demonstrated a favorable safety and tolerability profile.